血液透析患者矿物质骨代谢紊乱现状及其相关因素  

Status of Mineral Bone Metabolism Disorder and Its Related Factors in Hemodialysis Patients

作　　者：耿新洁 张争 张任重 GENG Xinjie;ZHANG Zheng;ZHANG Renzhong(Department of Haemodialysis,Shandong Zibo Central Hospital,Zibo 255000,China;Department of Nephrology,Shandong Zibo Central Hospital,Zibo 255000,China)

机构地区：[1]山东省淄博市中心医院血液净化科,淄博255000 [2]山东省淄博市中心医院肾病科,淄博255000

出　　处：《中国医药指南》2024年第19期116-118,共3页Guide of China Medicine

摘　　要：目的 评估血液透析患者的矿物质骨代谢紊乱现状及其相关因素。方法 选取2021年1月至2023年10月于我院实施血液透析的终末期肾脏病(ESRD)患者160例,分析血钙、血磷、钙磷乘积、全段甲状旁腺激素(iPTH)达标水平,对其达标的影响因素进行分析。结果 160例血液透析患者中,钙、磷、钙磷乘积、iPTH均达标的患者共18例(11.25%),余142例患者(88.75%)均存在程度不同的矿物质骨代谢紊乱。经对比,达标患者和非达标患者的年龄、性别、透析时长对比无统计学差异(P> 0.05),非达标患者合并高血压比例高于达标患者(P <0.05)。结论 血液透析患者中矿物质骨代谢紊乱情况十分常见,发生率高达近90%,高磷血症最为常见,合并高血压是血液透析患者矿物质骨代谢紊乱的影响因素。在为患者进行血液透析时,需要严密监测生化指标等,积极控制高血压,并提高对矿物质骨代谢紊乱等的认识,使得血液透析患者的生存质量得以提高。Objective To assess the current status of mineral bone metabolism disorders and their related factors in haemodialysis patients.Methods A total of 160 cases of end stage renal disease(ESRD) patients who underwent haemodialysis in our hospital from January 2021 to October 2023 were selected to analyse the attained levels of blood calcium,blood phosphorus,calcium-phosphorus product,and intact parathyroid hormone(iPTH),and the factors affecting the attainment of these levels were analysed.Results Among 160 haemodialysis patients,18 patients(11.25%) had calcium,phosphorus,calcium-phosphorus product,and iPTH compliance,and the remaining 142 patients(88.75%) had mineral bone metabolism disorders of varying degrees.Upon comparison,there was no statistical difference in the comparison of age,gender,and dialysis duration between patients who reached the standard and those who did not(P>0.05),and the proportion of combined hypertension was higher in patients who did not reach the standard than in those who did(P<0.05).Conclusions Mineral bone metabolism disorders are very common in haemodialysis patients,the incidence rate is up to nearly 90%,hyperphosphataemia is the most common,and combined hypertension is the influence factor of mineral bone metabolism disorders in haemodialysis patients.When patients undergo haemodialysis,it is necessary to closely monitor the biochemical indicators,actively control hypertension,and improve the understanding of mineral bone metabolism disorders,so that the quality of life of haemodialysis patients can be improved.

关 键 词：矿物质骨代谢紊乱 血液透析 终末期肾脏病 

分 类 号：R459.5[医药卫生—治疗学] R589.5[医药卫生—临床医学]